SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date of earliest event reported):
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of Principal Executive Offices and Zip Code)
telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 8.01||Other Events.|
On December 1, 2022, Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) received a grant payment of approximately $4.4 million from the Bill & Melinda Gates Foundation (the “Foundation”). The payment was made pursuant to our grant agreement with the Foundation, dated as of June 30, 2021, as amended (the “Grant Agreement”), under which we may receive up to a total of $48.95 million to support technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026 (the “Grant Period”) to advance DARE-LARC1 in nonclinical proof of principle studies. As of December 1, 2022, we have received a total of approximately $23.8 million in non-dilutive funding under the Grant Agreement.
Additional payments under the Grant Agreement are contingent upon the DARE-LARC1 program’s achievement of specified development and reporting milestones during the Grant Period.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|DARÉ BIOSCIENCE, INC.|
|Dated: December 5, 2022||By:||/s/ Sabrina Martucci Johnson|
|Name:||Sabrina Martucci Johnson|
|Title:||President and Chief Executive Officer|